Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The study evaluated the efficacy and safety of a prolonged, continuous course of
Valganciclovir (Valgan) in the prevention of CMV by comparing 3 months of Vaglanciclovir, the
standard of care upon initiation of the study, to 12 months of Valganciclovir.